Navigation Links
Anesiva Receives NASDAQ Delisting Staff Determination Letter
Date:7/23/2009

mber 2008, Anesiva announced that a Phase 3 clinical trial of Adlea achieved its primary efficacy endpoint of reduced post-surgical pain versus placebo (p=0.03) following total knee arthroplasty (TKA) at four to 48 hours after surgery. The trial also met its key secondary endpoint with Adlea demonstrating a highly significant reduction in opioid medication consumption compared to placebo (p=0.005).

The Phase 3 TKA trial, known as ACTIVE-2, also showed that Adlea's safety profile of adverse events, wound healing, and wound sensory function were similar to placebo over the study duration.

Forward-Looking Statements

Except for historical information, this press release may be deemed to contain "forward-looking" statements. Words such as "seek," "may," "will," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include the continued listing of Anesiva's common stock on The NASDAQ Global Market and matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the risk that Anesiva otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market as well as other risks detailed from time to time in Anesiva's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009. Anesiva expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
2. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
3. Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
4. Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
7. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
8. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
9. Anesiva Announces First Quarter 2008 Financial Results
10. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
11. Anesiva Announces Expansion of Zingo Agreement in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Working in collaboration with the ... London , Richmond Pharmacology is the first centre ... study for an investigational RNAi therapeutic being developed for the ... nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... solutions for the detection of foodborne pathogens, today ... and full year ended December 31, 2014. ... quarter ended December 31, 2014 was $1.4 million ... 2013 and $1.5 million for the third quarter ...
(Date:3/26/2015)... March 26, 2015  BioNano Genomics, Inc., the leader ... Salyer as chief commercial officer. Salyer has more ... sales teams in life sciences. At BioNano, Salyer will ... a genome-mapping platform to assemble a comprehensive view of ... To date, 32 institutions located in the ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced ... precision transit-time flow measurement solutions, are collaborating on a ... of the HeartAssist5® Left Ventricular Assist Device ... mobility and peace of mind. , The Transonic ... draw 1/6th of the power required by earlier flow ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Focus on Drug Development for Neurological ConditionsBROOMFIELD, Colo., ... delivering breakthrough therapies in central nervous system (CNS) ... Inc., a drug development company. The new ... of proprietary small molecule drugs for acute and ...
... Career and Technical Education (NRCCTE), funded by the Office of Vocational ... a report that focuses on the question: What Will Be the ... that centered on three questions: , , ... secondary and postsecondary instruction be articulated? , ...
... Expert Platforms for Translational Research , COLUMBIA, S.C., April ... Board: CLXS), a leading developer of semantic search and ... research portal www.BiomedExperts.com has blown ... surpass 150,000 by the end of April. The ...
Cached Biology Technology:Accera, Inc. Launches Neuera Pharmaceuticals, Inc. 2Accera, Inc. Launches Neuera Pharmaceuticals, Inc. 3What Will Be the Impact of Programs of Study? 2Collexis BiomedExperts Fast Approaching 150,000 Registered Users 2Collexis BiomedExperts Fast Approaching 150,000 Registered Users 3Collexis BiomedExperts Fast Approaching 150,000 Registered Users 4
(Date:3/12/2015)... -- IriTech, a leading iris based identity management technology ... Design Network, announced today that the Chief Minister ... MK2120U device during a launching event of Andhra Pradesh ... The iris scanner is manufactured by U.S. based ... India through its Indian partner, Biometronic Technology, ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year ... Unexpected, Hammacher Schlemmer introduces The Eye Scanning Password ... before granting access to secure websites or sensitive data. ... verify travelers at international borders, the device has a ... pattern points of the iris, converting them into an ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... University of North Carolina at Chapel Hill School of ... developed and experimentally tested a technique to predict new ... a computational method that compares how similar the structures ... binding partners -- known as ligands -- of disease ...
... WI, NOVEMBER 4, 2009 -- The world,s greatest wines are ... and something called the "terroir" -- a term often defined as ... discuss terroir with an emphasis on soil science in a symposium ... Environment" will be presented in two parts at the 2009 Annual ...
... LLEIDA, SPAINIn a research report published in a recent ... Sim Alegre examined the effects of covering orchard floors ... light distribution, orchard temperature, and profitability. The experiments were ... before commercial harvest in orchards of ,Mondial Gala, apples. ...
Cached Biology News:Study points to new uses, unexpected side effects of already existing drugs 2Great wines come from great soils 2Reflective film can boost profits for apple growers 2
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
... Reduce bench time to just 15 ... from the paralles that can be drawn between ... older idea of instant foods. Instant meals ... in freeze-dried format and are reconstituted by adding ...
APO(a) EIA Sample Size: 25 l...
Biology Products: